secwatch.observer — SEC 8-K summary
======================================

Issuer:     Neuraxis, INC (NRXS)
CIK:        0001933567
Form:       8-K
Filed at:   2025-10-24T23:59:59+00:00
Accession:  0001493152-25-019186
Event type: regulatory
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Neuraxis gets FDA 510(k) clearance for PENFS to treat functional dyspepsia in ages 8+
--------------------------------------------------------------------------------

- FDA cleared Neuraxis' PENFS for functional abdominal pain associated with functional dyspepsia and nausea in patients 8 years and older.
- This is the first FDA clearance or approval specifically addressing functional dyspepsia in adults.
- Clearance based on RCTs and real-world evidence; FDA extrapolated pediatric data to adults.
- Company increased ATM offering from $3.3M to $6.27M; no shares sold under prior agreement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1933567/000149315225019186/0001493152-25-019186-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1933567/000149315225019186/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-019186

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer